(MM-141-07-0202) A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of MM-141 Plus Nab-Paclitaxel and Gemcitabine Versus Nab-Paclitaxel and Gemcitabine in Front-Line Metastatic Pancreatic Cancer (CARRIE)

To determine whether the combination of MM-141 plus nab-paclitaxel
and gemcitabine is more effective than nab-paclitaxel and gemcitabine
alone based on Progression Free Survival (PFS) in front-line
metastatic pancreatic cancer patients with:
o High serum levels of free IGF-1
o High serum levels of free IGF-1 and pre-treatment tissue samples positive for Heregulin (HRG)

Study Number: 

PH 269615

Principal Investigator: 
ClinicalTrials.Gov ID: 

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.